Risk factors for the development of neurotoxic syndromes from the use of CAR-T cells: An integrative review
DOI:
https://doi.org/10.33448/rsd-v14i6.49076Keywords:
Adoptive Cellular Immunotherapy, Chimeric Antigen Receptor Therapy, CAR T Cells Therapy, Risk Factors, Neurotoxic Syndromes.Abstract
CAR-T immunotherapy is an innovative and technologically complex treatment that has proven effective in hematopoietic cancers. However, adverse effects such as neurotoxic syndromes may occur. The objective of this study was to analyze the risk factors associated with the development of neurotoxic syndromes after CAR-T immunotherapy infusion. This is an integrative review with a qualitative and exploratory approach. The research was conducted in the PubMed database, between 2020 and 2025, using the search strategy: “CAR-T Cell* Therapy” OR “Immunotherapy AND CAR-T Cell*” AND “Neurotoxicity Syndrome*” OR “Cell-Associated Neurotoxicity”; PRISMA2020 criteria were used, and after applying inclusion and exclusion criteria, the selected studies were qualitatively analyzed according to the steps of Discursive Textual Analysis. After applying the inclusion and exclusion criteria, 13 articles were selected to compose the study. The factors associated with higher risks of CRS and ICANS due to CAR-T immunotherapy identified are: types of CAR products, inflammatory interleukins released simultaneously, high tumor burden, acute kidney injury, sepsis, history of neurological injury, abrupt onset of neurotoxic symptoms, and high lactate dehydrogenase rates. It is inferred that several factors influence the risks of neurotoxicities, contributing to the complexity of this effect, making it necessary to conduct additional studies to deepen the understanding of the mechanisms involved, identify other possible risk factors, and enable the standardization of pharmacological management protocols for affected patients.
Downloads
References
BioRender Inc. (2025). BioRender.com (Versão de 10 de junho de 2025) [Software de criação de imagem]. https://BioRender.com. Link de acesso a imagem criada: https://app.biorender.com/illustrations/6848abef7324c7f059bfed05?slideId=16e1df06-eac5-411d-b1f1-fdb12f26eeb3.
Boulch, M., et al. (2023). A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Reports Medicine, 4(9), 101161.
Bui, T. A., et al. (2024). Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine, 106, 105266.
Butt, O. H., et al. (2024). Neuroaxonal injury, but not astrocyte injury, is associated with CAR T cell related ICANS. Transplantation and Cellular Therapy, 30(2), S215.
Chen, T., et al. (2024). Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell International, 24(1), 133.
Chishinga, N., Mapalo, M. T., & Bodine, C. D., Jr. (2024). Risk stratification for immune effector cell-associated neurotoxicity syndrome in patients receiving chimeric antigen receptor T cell therapy. Journal of Clinical Oncology, 42(16_suppl), e14534.
Chohan, K. L., Siegler, E. L., & Kenderian, S. S. (2023). CAR-T cell therapy: The efficacy and toxicity balance. Current Hematologic Malignancy Reports, 18(2), 9–18.
Gatto, L., et al. (2023). CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: Fill the gap. Frontiers in Oncology, 13, 1206983.
Grant, S. J., et al. (2022). Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: A systematic review. Transplantation and Cellular Therapy, 28(6), 294–302.
Hosseini, M.-S., et al. (2024). Formulating research questions for evidence-based studies. Journal of Medicine, Surgery, and Public Health, 2, 100046.
Kewan, T., et al. (2023). CAR T-related toxicities based on dynamic proteomic profiles identifies risk factors for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Blood, 142(Supplement 1), 2132.
Kutcher, A. M., & LeBaron, V. T. (2022). A simple guide for completing an integrative review using an example article. Journal of Professional Nursing, 40, 13–19.
Larue, M., et al. (2024). Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy. Journal for Immunotherapy of Cancer, 12(9), e009139.
Marofi, F., et al. (2021). Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Research & Therapy, 12(1), 465.
Moraes, R., & Galiazzi, M. C. (2016). Análise textual discursiva (3rd ed.). Editora Unijuí.
Morris, E. C., et al. (2022). Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology, 22(2), 85–96.
Page, M. J., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71.
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Editora UAB/NTE/UFSM.
Rejeski, K., et al. (2024). Immune effector cell-associated haematotoxicity after CAR T-cell therapy: From mechanism to management. The Lancet Haematology, 11(6), e459–e470.
Shouval, R., et al. (2023). Predictors of cytokine release syndrome and neurotoxicity in patients with large B-cell lymphoma and their impact on survival. Blood, 142(Supplement 1), 355.
Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of business research, 104, 333-339.
Sterner, R. C., & Sterner, R. M. (2022). Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Frontiers in Immunology, 13, 879608.
Velasco, R., et al. (2023). CAR-T cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern? Frontiers in Neurology, 14, 1144414.
Zhong, Y., & Liu, J. (2024). Emerging roles of CAR-NK cell therapies in tumor immunotherapy: Current status and future directions. Cell Death Discovery, 10(1), 318.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Leandro Maia Leão; Josemir de Almeida Lima; Uirassú Tupinambá Silva de Lima; Helder Delano Barboza de Farias; Vívian Marcella dos Santos Silva; Yolanda Gomes Torres Pinto; Marcos Darlan Balbino Ferreira; Luciana da Silva Viana
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
